Trial Profile
Re-examination Study For General Drug Use to Assess the Safety and Efficacy Profile of EMEND in Usual Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary)
- Indications Nausea and vomiting
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 04 Oct 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
- 22 Dec 2011 Actual patient number is 3482 according to ClinicalTrials.gov.
- 22 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.